Focal Nodular Hyperplasia and Hepatocellular Adenoma around the World Viewed through the Scope of the Immunopathological Classification

Table 2

IHC in benign liver nodules.

(a) LFABP

	T	NT
H-HCA	− (a)	+ (b)
β-HCA, IHCA, β-IHCA, UHCA	+	+
FNH	+	+
MNR/MNR-FNH-like (cirrhosis)	+	+

(a) Some hepatocytes may be positive at the periphery of the nodule, as well as in between 2 coalescent nodules.
(b) When the expression is weak, reading may be difficult.

(b) CRP

	T	NT
IHCA, β-IHCA	+ (a)	− (b)
H-HCA, β-HCA, UHCA	−	− (b)
FNH	− (b^')	− (b)
MRN/MRN-HNF-like (cirrhosis)	(c)	(d)

(a) Staining can be heterogeneous.
(b) Can be positive (in case of hemorrhage/necrosis, inflammatory syndrome; portal branch embolization, etc.).
(b^') Can be positive if (b) is positive.
(c) Often positive (weak/mild).
(d) Negative to positive (weak to mild), heterogeneous from nodule to nodule.

(c) GS

	T	NT
FNH	+ (a)	(b)
MRN/MRN FNH-like (cirrhosis)	(c)	(d)
β-HCA, β-IHCA	+ (e)	(b)
H-HCA, IHCA, UHCA	−	(b)

(a) Map-like pattern.
(b) Normal positivity around central veins (1–3 rows).
(c) From absence to positivity (limited to veins and/or border of fibrous axis).
(d) Negative, occasional faint staining.
(e) Strong and diffuse or heterogeneous.